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ABSTRACT: Persistent pulmonary hypertension of the newborn (PPHN) is an essential cause for hypoxic respiratory failure with significant
morbidity and mortality in term and near-term neonates. Hydrocortisone has been shown to decrease oxygen dependency and pulmonary
hypertension in neonates with meconium aspiration syndrome and animal studies, respectively. We hypothesize that hydrocortisone will improve
oxygenation in term and near-term infants with pulmonary hypertension. We performed a retrospective chart review of all infant with PPHN who
received intravenous hydrocortisone therapy as a rescue for severe PPHN. Clinical response was objectively measured using, oxygenation
index (OI), PaO2/FiO2 ratio, and inotrope score before, during, and after the hydrocortisone course. We found that hydrocortisone administration
resulted in significant improvement of systolic blood pressure, OI, and PaO2/FiO2. In conclusion, hydrocortisone increased systolic blood
pressure and improved oxygenation in term and near-term infants with persistent pulmonary hypertension. Prospective randomized trials are
required to evaluate these findings further.
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Background

conducted a retrospective chart review to evaluate the impact
of intravenous (IV) HC in infants with severe PPHN on oxygenation and systolic blood pressure (SBP). We hypothesized
that HC would increase SBP, decrease the right-to-left shunting, and improve oxygenation.

Persistent pulmonary hypertension of the newborn (PPHN) is
an essential cause for hypoxic respiratory failure with significant morbidity and mortality in term and near-term neonates.1,2 It is a complex syndrome characterized by high
pulmonary vascular resistance (PVR) to suprasystemic levels
resulting in the extrapulmonary right-to-left shunting of blood
leading to severe hypoxemia.3-5 Current standard therapy of
PPHN includes supplemental oxygen, ventilation of the lung,
hemodynamic support to maintain systemic vascular resistance,
and inhaled nitric oxide (iNO) to reduce PVR.6,7 However,
some infants do not respond to these measures necessitating
the use of extracorporeal membrane oxygenation (ECMO),
with the hope to allow enough time for lung vasculature to
recover.8,9 Experimental studies both in animals and humans
have shown that hydrocortisone (HC) can reduce the inflammatory process, stabilize systemic blood pressure, improve the
cardiovascular stability in neonates with hypotension and low
perfusion.10-12 Postnatal systemic steroids have been shown to
decrease the duration of hospital length of stay and oxygen
dependence in meconium aspiration syndrome (MAS).13 In
the fetal lamb model of PPHN, HC treatment postnatally has
been shown to improve oxygenation, increase cGMP levels,
and reduce reactive oxygen species (ROS) levels.14 In spite of
these effects, the role of HC in the management of PPHN,
due to causes other than MAS in neonates is not clear. We

Methods

We conducted a retrospective chart review of all infants admitted to a level 4, neonatal intensive care unit (NICU) from
January 2010 to June 2017. Term or near-term infants
⩾35 weeks of gestational age with the diagnosis of PPHN were
included in the study. The diagnosis of PPHN was confirmed
by echocardiography demonstrating elevated pulmonary arterial pressure (right-to-left shunting of blood at patent foramen
ovale or ductus arteriosus, tricuspid regurgitation, and dilated
right side of the heart with or without decrease right ventricular
function).15 Only infants with PPHN and who received HC
rescue for management of PPHN were reviewed and analyzed.
Infants with congenital malformations or those who died within
the first 24 hours after life were excluded from the study. Severity
of the hypoxemic respiratory failure (HRF) was determined by
two measures: oxygenation index (OI) = Fraction of inspired
oxygen concentration (FiO2) × mean airway pressure
(MAP) × 100/partial pressure of oxygen in the arterial blood in
mmHg (PaO2) and PaO2/FiO2 ratio (P/F ratio). A higher OI
and a lower P/F ratio would indicate the severity of HRF.
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Inhaled nitric oxide was started per unit protocol at 20 parts per
million with echocardiographic evidence of PPHN and an OI
of >15 by at least 2 arterial blood gases 4 hours apart after optimizing mechanical ventilation (partial pressure of carbon dioxide [pCO2] of 40-50 mm Hg and 8 ribs or more lung inflation
on chest radiograph). Systemic hypotension was defined as a
mean arterial blood pressure of less than the gestational age at
the timepoint of measurement. Infants with hypotension were
treated with inotropic agents per the discretion of the attending
physician. Infants who failed to respond to the measures as
mentioned above were started on IV HC (initial dose of 4 mg/
kg/dose followed by 1 mg/kg/dose given every 6 hours for
48 hours). The response to HC on oxygenation and hemodynamics was trended by calculating the OI at several timepoints:
before administration of HC; 6 hours into HC therapy; 24 hours
into therapy, and 24 hours after completion of the therapy.
Systolic blood pressures were collected, the inotrope scores
(cumulative mean of dopamine dose (mcg/kg/min) + dobutamine dose (mcg/kg/min) + 100 × epinephrine dose (mcg/kg/
min)) were calculated,16 and PaO2/FiO2 ratios were noted at the
same timepoints. The demographic and clinical characteristics
of the infants with PPHN who received HC treatment were
recorded.
Data expressed as mean ± standard deviation, with n being
the number of infants studied. We performed student t-test
and analysis of variance with Fisher’s Post hoc testing when
appropriate (SAS Systems, Cary, NC, USA) for data analysis.
P-value < .05 was considered significant.

Ethical approval and informed consent
This study was approved by the ethics committee of University
at Buffalo (Approval No. 030-753144). Informed consent
requirement was waived as we analyzed the data with no identifiable private information.

Results

We identified 15 infants with PPHN who receive intravenous
HC during the study period. All infants received iNO before
HC treatment (Table 1). All infants were treated with dopamine as inotrope before HC administration. Milrinone was
started on 7 infants (7/15, 46%) before HC administration.
Two infants with severe PPHN did not respond to medical
management and required ECMO support. In total, 7 infants
(7/15, 47%) had asphyxia as the primary cause for PPHN, out
of which 5 underwent whole body hypothermia. None of the
infants included had intestinal perforation or necrotizing
enterocolitis. Systolic blood pressure increased significantly
with HC and remained elevated even after discontinuation of
HC. In addition; there was a significant decrease in inotropic
support as measured by inotropic score following initiation of
HC (Figure 1). Significant reduction in OI, and an increase in
PaO2/FiO2 ratio (Figure 2) were also observed in these infants.
In attempt to identify a correlation between the SBP and P/F

Table 1. Baseline and clinical characteristics of infants with PPHN
who received hydrocortisone.
Gestational age in weeks

38.2 ± 1.6

Birth weight (g)

2991 ± 650

Sex (male) n (%)

12 (80)

Normal vaginal delivery n (%)
Cord pH
APGAR at 5 minutes (range)

9 (60)
7.05 ± 0.28
6 (1-9)

Etiology of PPHN
Asphyxia n (%)

7 (47)

MAS n (%)

2 (13)

Pneumonia or sepsis n (%)

6 (40)

Surfactant n (%)

11 (73)

Dopamine n (%)

15 (100)

Inhaled NO n (%)

15 (100)

Milrinone n (%)

7 (46)

ECMO n (%)

2 (13)

Abbreviations: APGAR, Appearance, Pulse, Grimace, Activity, and Respiration,
PPHN, persistent pulmonary hypertension, ECMO, extracorporeal membrane
oxygenation; MAS, meconium aspiration syndrome; NO, nitric oxide.
Values are presented as mean ± standard deviation unless reported otherwise
(Figures 1-3).

ration, we demonstrated a linear relationship between the two
parameters (PaO2/FiO2 ratio and systolic blood pressure)
(Figure 3), which could explain the significant improvement
overtime noted after HC administration.

Discussion

To our knowledge, this is the first clinical study to evaluate the
effects of intravenous HC in infants with severe PPHN due to
all medical causes (Congenital anomalies were excluded). A
course of HC in infants not responding to iNO and inotropes
resulted in a significant improvement in SBP and oxygenation
in our study. The findings suggest a potential role of HC in
infants with PPHN and hypoxic respiratory failure and hypotension refractory to the conventional treatment.
Hydrocortisone is a commonly used medication in neonates
for its anti-inflammatory properties. Common indications
for HC in the NICU include bronchopulmonary dysplasia (or
severe lung disease with the goal of extubation), systemic hypotension, and adrenal insufficiency.17-20 Majority of studies evaluating HC in the NICU have been conducted in preterm
infants. A randomized trial to study HC in term infants was
closed early due to low recruitment.21 Methylprednisolone
decreased the length of stay with a rapid reduction in oxygen
dependence and clearance of X-ray abnormalities in infants
with MAS. The dose of methylprednisolone administered
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Figure 1. (A) Systolic blood pressure changes over time before and after the hydrocortisone (HC) administration. (B) Inotrope score overtime before and
after hydrocortisone administration. *P value <.001 compared with before HC administration.

Figure 2. (A) Oxygenation index changes overtime before and after the hydrocortisone (HC) administration. (B) PaO2/ FiO2 ratio changes overtime before
and after hydrocortisone administration. *P < .001 compared with before HC administration.

Figure 3. Correlation between PaO2/FiO2 ratio and systolic blood
pressure. Significant linear correlation was demonstrated between
systolic blood pressures and P/F ratio (r2 = 0.504; P < .001). P/F indicates
PaO2/FiO2.

(0.5 mg/kg/day divided q 12 hours) was equivalent to HC used
in our study.13 Interestingly, these patients with MAS enrolled
in this study has a high incidence of sepsis (1/3 had a positive
blood culture), but the frequency was not higher in the steroid
group. In contrast, these results are not consistent with Yeh

et al. showing no improvement in oxygenation with HC
(10 mg/kg q 12 hours × 4 doses) in MAS.22 In spite of such a
high dose of HC, there was no difference in oxygenation or
radiological clearance. Infants with MAS who received HC
took a more extended period to wean to room air and had prolonged respiratory distress compared with the placebo group.
However, it is not clear if infants in either of these studies had
evidence of PPHN by echocardiography.
In animal models of PPHN, we have shown that HC treatment improves oxygenation and decreases hyperoxia-induced
changes in PDE5 activity and increasing cGMP levels in
lambs with PPHN.14 A decrease in pulmonary phosphodiesterase 5 activity (an enzyme that converts cGMP to inactive
5′GMP), with increasing levels of cGMP results in smooth
muscle relaxation.14 Hydrocortisone also reduces ROS levels
in part by increasing superoxide dismutase activity in PPHN
lambs ventilated with 100% O2.14
Glucocorticoids improve oxygenation and attenuate pulmonary hypertensive response in animal models of meconium
aspiration.23 Improvement in oxygenation with HC can also be
explained by its effect on the systemic blood pressure, as shown
in our study.24 This effect persisted even after the discontinuation of HC treatment. The increase in SBP was associated with
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an improvement in oxygenation as measured by the P/F ratio
and the OI. An increase in SBP can result in decreasing the
right-to-left shunting at both the ductal and atrial levels.
Increased systemic pressure can also improve the coronary
arterial perfusion, which plays a critical role to support the
function of the right ventricle to pump unoxygenated blood to
the lungs. Finally, dopamine is a nonselective vasoconstrictor
agent and can increase pulmonary arterial blood pressure.
Weaning of dopamine following HC therapy may have played
a role in increased pulmonary blood flow and oxygenation.
This study has several significant limitations, including its
small sample size and is a retrospective study. Both of these
limitations can result in the possibility of confounding variables that could affect outcomes. Echocardiogram was not
performed at regular intervals to assess the effects of HC on
pulmonary arterial pressures and right-to-left shunting in our
cohort. We relied on indirect measures of severity of lung disease and PPHN by measuring P/F ratio and OI during and
after HC. However, all infants had an echocardiogram before
HC to confirm the diagnosis of PPHN. Follow up echocardiograms were obtained until the resolution of the PPHN.
Cortisol levels were not obtained before HC initiation. In
spite of these limitations, we observed that HC increased SBP
and improved OIs.
In conclusion, HC increases SBP and improves oxygenation
as measured by OI and P/F ratio. Increase in SBP with a reduction in right-to-left shunt may contribute partly to improvement in oxygenation in PPHN. Prospective randomized trials
are required to evaluate the role of HC therapy in infants with
PPHN.

Author Contributions

MA: conceptualized and designed the study, collected, analyzed and interpreted the data; drafted the initial manuscript
and reviewed and revised the manuscript.
SL, VHSK: conceptualized the study design, contributed to
analyses and interpretation of data, and revising the manuscript
for critically important intellectual content.
AM: Collected, analyzed and interpreted the data, and reviewed
the manuscript.

ORCID iD

Mahdi Alsaleem

https://orcid.org/0000-0002-2285-2963

References
1.

2.
3.
4.
5.
6.
7.
8.
9.

10.
11.
12.
13.
14.
15.
16.

17.
18.
19.
20.
21.
22.
23.
24.

Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph
AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr. 1976;
89:626-630.
Mathew B, Lakshminrusimha S. Persistent pulmonary hypertension in the newborn. Children (Basel). 2017;4:63.
Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn. NeoReviews. 2015;16:e680-e692.
Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med.
2010;11:S79-S84.
Teixeira-Mendonca C, Henriques-Coelho T. Pathophysiology of pulmonary
hypertension in newborns: therapeutic indications. Rev Port Cardiol. 2013;32:
1005-1012.
Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment.
Semin Perinatol. 2014;38:78-91.
Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child
Fetal Neonatal Ed. 2012;97:F223-F228.
Lazar DA, Cass DL, Olutoye OO, et al. The use of ECMO for persistent pulmonary hypertension of the newborn: a decade of experience. J Surg Res. 2012;177:
263-267.
Van Berkel S, Binkhorst M, Van Heijst A, Liem D. Adapted ECMO entry criteria for newborns with persistent pulmonary hypertension (PPHN) following
treatment with inhaled nitric oxide (INO) and/or high-frequency oscillatory
ventilation (HFOV). Pediatr Res. 2011;70:744.
Seri I. Hydrocortisone is effective in treatment of vasopressor-resistant hypotension in very low birth weight neonates. J Pediatr. 2006;149:422-423.
Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in
preterm infants. Cochrane Database Syst Rev. 2011;12:CD003662.
Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288:
886-887.
Tripathi S, Saili A. The effect of steroids on the clinical course and outcome of
neonates with meconium aspiration syndrome. J Trop Pediatr. 2006;53:8-12.
Perez M, Lakshminrusimha S, Wedgwood S, et al. Hydrocortisone normalizes
oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol. 2012;302:L595-L603.
Jone P-N, Ivy DD. Echocardiography in pediatric pulmonary hypertension.
Front Pediatr. 2014;2:124-124.
Gaies MG, Jeffries HE, Niebler RA, et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric
Cardiac Critical Care Consortium and Virtual PICU System Registries. Pediatr
Crit Care Med. 2014;15:529-537.
Pulmonary effects of neonatal hydrocortisone treatment in ventilator-dependent
preterm infants. Int J Pediatr. 2011;2011:783893.
Altit G, Vigny-Pau M, Barrington K, Dorval VG, Lapointe A. Corticosteroid
therapy in neonatal septic shock-do we prevent death? Am J Perinatol. 2018;35:
146-151.
Watterberg KL. Hydrocortisone dosing for hypotension in newborn infants: less
is more. J Pediatr. 2016;174:23-26.e21.
Watterberg KL, Gerdes JS, Gifford KL, Lin H-M. Prophylaxis against early
adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104:1258-1263.
Watterberg KL, Fernandez E, Walsh MC, et al. Barriers to enrollment in a randomized controlled trial of hydrocortisone for cardiovascular insufficiency in
term and late preterm newborn infants. J Perinatol. 2017;37:1220-1223.
Yeh T, Srinivasan G, Harris V, Pildes R. Hydrocortisone therapy in meconium
aspiration syndrome: a controlled study. J Pediatr. 1977;90:140-143.
Soukka H, Halkola L, Aho H, Rautanen M, Kero P, Kaapa P. Methylprednisolone attenuates the pulmonary hypertensive response in porcine meconium aspiration. Pediatr Res. 1997;42:145.
Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn. Matern Health Neonatol Perinatol. 2015;1:14.

